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Summary The inﬂuence of pharmaceuticals on the environment is an increasing
concern among environmental toxicologists. It is known that their growing use is
leading to detectable levels in wastewater, conceivably causing harm to aquatic
ecosystems. Psychotropic medication is one such group of substances, particularly
aﬀecting high-income countries. While these drugs have a clear place in therapy,
there is debate around the risk/beneﬁt ratio in patients with mild mental health
problems. Therefore, it is necessary to evaluate the wider implications as risks could
extend beyond the individual to non-target organisms, particularly those in rivers and
estuaries.
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Psychotropic drug use patterns
Adequate psychiatric service provision is central to health
and quality of life, and the use of psychotropic medication
can be invaluable in the treatment and management of
mental health problems. The uses of these drugs have
been evident since their introduction, and they have a well-
established place in clinical practice. However, within the
medical ﬁelds, there has been a debate in recent years about
the over-reliance on drugs such as antidepressants, antianxi-
ety drugs and antipsychotics.1–4 Data from a number of coun-
tries have indicated rapid rises in prescriptions, with as many
as 10% of the population taking such medications, particularly
in high-income countries such as the UK.3 Within the ﬁeld of
environmental toxicology, the eﬀects of these drugs have
recently started to generate some interest too.
Pharmaceuticals as emergent pollutants
Currently, pharmaceuticals mainly enter the environment
through wastewater after their excretion, either in their ori-
ginal form or as metabolites. This has long been known,5,6
with the ﬁrst reports of these substances entering the envir-
onment dating back to the 1960s.7 However, sewage
treatment plant processes do not adequately remove phar-
maceuticals. With the sheer number of diﬀerent medications
being prescribed and the inability of even quite modern sew-
age treatment processes to fully break them down, it could
be argued that our aquatic life is bathing in a soup of mul-
tiple drugs.
Toxicity levels of pharmaceuticals in the environment
do not necessarily relate to high concentrations, but to
their constant low-level discharge, persistence in ecosystems
and highly active biological functions. In this way, pharma-
ceuticals that are found in relatively low concentrations
could be extremely potent and very persistent, and able to
signiﬁcantly aﬀect non-target organisms. For example, low
concentrations of antidepressants and other psychotropic
drugs can cause disruption to the normal functioning of
aquatic organisms.8
The concept of environmental relevance, therefore,
becomes important. For example, selective serotonin
reuptake inhibitors, selective serotonin–noradrenaline
reuptake inhibitors, serotonin antagonist reuptake inhibi-
tors, tricyclic antidepressants and benzodiazepines have all
been detected in urbanised waterways, mostly in the ng/L
range, but also in concentrations up to μg/L.7 What is par-
ticularly starting to interest scientists is that these antide-
pressants can cause disruption to the normal functioning
of aquatic life in laboratory experiments at low concentra-
tions. The uptake of these compounds appears to be highly
dependent on the organism’s mode of feeding.9 In terms of
presence in the environment, for example, diazepam has
been found in all matrices – wastewater, surface, ground
and drinking water, soils, bio-solids and tissues10 – and in
concentrations as high as 10 ng/L in rivers and potable
water.11
Pharmaceuticals are not present in isolation in the envir-
onment, and the widespread high use of a wide variety of
drugs leads to multiple substances being found together, in a
situation where synergistic or antagonistic eﬀects can occur.7
In addition, exposure of some non-target organisms to these
substances takes place for the entirety of their life cycle.12
Currently, pharmaceuticals and their active metabolites are
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globally considered to be an important emergent group of pol-
lutants that are intrinsically bioactive, causing adverse drug
reactions and previously undocumented eﬀects on non-target
organisms.7
The eﬀects of psychotropic drugs on the aquatic
environment
The notion that drugs prescribed to humans might be aﬀect-
ing wildlife ﬁrst came to light in the 1990s, when scientists
highlighted that natural and synthetic oestrogens from
contraceptive pills and hormone replacement therapy in
wastewater eﬄuent could feminise ﬁsh at very low concen-
trations.13 Growing incidences of reproductive and other
abnormalities developed into an interdisciplinary ﬁeld, link-
ing human and environmental toxicology to the study of
endocrine-disrupting chemicals. As improved analytical
techniques become available and interest in this ﬁeld
increases, the inﬂuence of pharmaceuticals on the environ-
ment is increasingly being documented. Identiﬁed cases
where pharmaceuticals are causing detrimental eﬀects are
therefore becoming more common. For example, the veter-
inary use of the non-steroidal anti-inﬂammatory drug diclo-
fenac has recently been linked to widespread (over 90%)
declines in vulture species in some countries14 and serves
as a reminder that, sometimes, the eﬀects of biologically
active drugs can have far-reaching consequences.
While the potential for pharmaceuticals to lead to tox-
icity in non-target organisms exists across all therapeutic
groups, the case of psychotropic medication is particularly
concerning. This is because these drugs, which are among
the most commonly detected in aquatic environments, aﬀect
not only the central nervous system but are also linked with
reproduction, growth and immune functions.13,15 In this way,
psychotropic drugs such as antidepressants modulate neuro-
transmitters serotonin, dopamine and noradrenaline, having
multiple physiological eﬀects in humans such as weight gain,
fatigue and sexual dysfunction.
The ability of psychotropic medication to disrupt the nor-
mal biological systems of abundant and ecologically import-
ant groups of non-target organisms in aquatic environments
is extensive. Since reuptake transporters and receptors
evolved in invertebrates such as molluscs and Crustacea,
release of neurohormones would be expected to have multiple
biological eﬀects on these invertebrates, in addition to verte-
brates such as ﬁshes. Therefore, any compounds in the envir-
onment at a suﬃcient concentration able to alter
neurohormones have the capacity to aﬀect a wide range of
biological processes,16 leading to salient eﬀects on critical
life cycle events. Processes aﬀected include reproduction,
growth, maturation, metabolism, immunity, feeding, locomo-
tion, colour physiology and behaviour. Examples of adverse
eﬀects that have been observed include photo- and geotactic
behaviour, abnormal activity patterns, aggressive behaviour,
developmental and metabolic abnormalities, and reproductive
abnormalities. Interestingly, some of these eﬀects are only
exhibited at low concentrations, rather than being dose
dependent as may have been expected.16
For example, Guler and Ford17 studied the eﬀects of a
variety of pharmaceuticals and the hormone serotonin on
the preference for light versus dark choice chambers in
amphipods. They reported a signiﬁcant preference for light
and response to gravity in terms of position in amphipods
exposed to ﬂuoxetine and serotonin. The dose response
was linear for serotonin, whereas for ﬂuoxetine the response
was not dose dependent and the behaviour was induced only
at lower concentrations (10–100 ng/L). Similarly, when crabs
were injected with serotonin, photonegative behaviour was
reduced and they spent substantially less time hidden.16
This would have consequences for aquatic life, as preference
to light has been demonstrated to increase the likelihood of
predation.
Other studies found that while 1 ng/L ﬂuoxetine inﬂu-
enced learning in the cuttleﬁsh, 100 ng/L did not, but did
signiﬁcantly inﬂuence the retention of memory. Eﬀects
observed include ﬂuoxetine inﬂuencing on learning and
memory in cuttleﬁshes at concentrations between 1 and
100 ng/L.18 Swimming activity has been observed to
be altered in amphipod crustaceans at levels as low as
1–100 ng/L,19 and gonadal aberrations in zebra mussels
have been induced in ranges as low as 20 ng/L. Moreover,
ﬂuvoxamine was found to induce egg deposition in zebra
mussels at ∼318 ng/L,20 and exposure to venlafaxine has
caused foot detachment (an inability to cling to the side of
a tank) at levels as low as 313 pg/L and 31.3 ng/L.21,22
Further eﬀects on reproductive output in terms of frequency
of broods, oﬀspring production, gamete release and gene
expression have been demonstrated in the ng/L
concentrations.
Induction of hyperglycaemic responses in a variety of
crustaceans has also been observed. The regulation of
blood glucose through crustacean hyperglycaemic hormone
is under the control of a variety of neurohormones.23
There have also been reports that dopamine, serotonin, nor-
adrenaline and adrenaline are all eﬀective in inducing hyper-
glycaemic responses in a variety of crustaceans.24 The
release of crustacean hyperglycaemic hormone has been
shown to be promoted by injection with serotonin in a
variety of species.23 Interestingly, studies with crabs have
shown that both serotonin and ﬂuoxetine can stimulate
crustacean hyperglycaemic hormone and suppress moulting
hormones.25 In terms of pigmentation, serotonin has been
shown to inﬂuence red pigment-dispersing hormone, while
dopamine inﬂuences red and black pigment-concentrating
hormones in shrimp. It has also been found that noradren-
aline triggers release of black pigment-dispersing hor-
mone.23 Therefore, any drugs with the capability to
modulate these neurohormones can conceivably interfere
with the camouﬂage abilities of aquatic invertebrates.
Perhaps it is not surprising that ﬁsh exposed to antide-
pressants or antianxiety medication display altered behaviours
when one considers how evolutionarily conserved the nervous
system is among the vertebrates. Furthermore, because of this
conserved ancestry, ﬁsh are now more commonly used in drug
discovery, with behavioural tests commonly used in rats and
mice being translated to ﬁsh models.26,27 For example, the
novel tank test measures the ‘normal’ reluctance of a ﬁsh to
venture in the open surroundings of a new tank, which can
be altered by antianxiety medication.28,29 Other studies within
the ﬁeld of environmental toxicology have observed a wide
range of altered behaviours in ﬁsh, including aggression
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towards conspeciﬁcs,30,31 reproduction,32,33 predator avoid-
ance34 and feeding.35
A body of evidence is therefore building which suggests
that antidepressants in particular, at concentrations found in
surface, waste and ground waters, can cause a wide variety of
eﬀects. Whether these are occurring in the ﬁeld downstream
of wastewater treatment plants (WWTPs) represents an
important and challenging question to address, as the ability
to measure abnormal behaviour in situ remains a logistical
and technological challenge. Moreover, while the underlying
role of neurotransmitters has been described in vertebrates,
there is considerable paucity of data on their role in inverte-
brates.16 The non-monotonic dose responses shown by some
drugs,17,18,36–38 for which pharmacological eﬀects are not dose
dependent and a response is triggered by a low concentration,
with no response to higher concentrations, poses questions
which are diﬃcult to ignore.39 While some studies have been
conducted on the toxicology of antidepressants such asﬂuoxet-
ine,16 these are few and far between. Given the evidence on the
inﬂuence of pharmaceuticals, particularly psychotropic drugs,
on the environment, it can be argued that greater emphasis
should be placed on how they may be aﬀecting aquatic life.
The solutions
The solutions to these problems, as might be expected, are
multifactorial and somewhat inﬂuenced by historical deci-
sions. For example, some WWTPs may have historically ser-
viced small towns and villages which later grew in
population into large towns and cities. If these WWTPs his-
torically discarded their eﬄuent into small (low ﬂow) rivers,
then the eﬄuent to river water ratios could change over
time. Changes in water usage upstream, for example, water
extraction for farming, could further confound the problem.
Advanced treatment at wastewater treatment facilities
would reduce many of the potentially harmful pharmaceuti-
cals waste products and their breakdown metabolites. Where
technological improvements of sewage treatment have been
implemented, there have been reductions in intersex (femin-
ised) ﬁsh caused by steroid oestrogens and their mimics,
as well as improvements in river biodiversity.40,41 These
improvements, however, are costly. Owen and Jobling
(2012)42 estimated that upgrading all the WWTPs in
England and Wales to comply with EU regulation to bring
synthetic oestrogens below an average of 0.035 pg/L ethiny-
lestradiol per annum would cost an estimated £26 billion.
Another solution to this complex problem is to change
behaviours whereby people would traditionally ﬂush their
unwanted medications down the toilet or dispose of them
in the bin. ‘Take back’ programmes vary in their popularity
across Europe, but serve as one means to prevent unwanted
medication entering aquatic systems directly following was-
tewater treatment or indirectly through underground seep-
age from landﬁlls. The question of green pharmacy has
also been raised, whereby the pharmaceutical industry con-
siders the cradle-to-grave approach of their products and
designs drugs which readily break down. However, this is
extremely diﬃcult to achieve for most drugs, owing to the
need to produce pharmacologically active pharmaceuticals
in suitable formulations.43
Reﬂections for policy and practice
Mental healthcare services are provided through complex
systems, which are generally based around the use of medi-
cation, with training in psychiatry covering vast areas to
enable the provision of quality care to patients. However,
there is no inclusion of aspects of pollution and the eﬀects
of psychotropic medication, and how this could aﬀect
aquatic environments. Could educating the medical profes-
sion help improve the utility of take back programmes and
patient behaviour with regard to drug waste? These sub-
stances are not currently covered by existing regulations
with regards to sewage management, and analytical methods
for detection are just now becoming available. Adequate
resources for the diagnosis and management of mental
health conditions could help reduce the need for medication
and the documented toxic eﬀects of the use of these drugs
on non-target organisms. ‘Prescribing’ psychotropic medica-
tion for our rivers and estuaries poses a potential risk to
aquatic life. Further knowledge and education on adequate
therapeutic choices, and improved resources for diagnosis,
could support prescribers and practitioners to make envir-
onmentally sensible choices, based on evidence of eﬃcacy
and safety.44
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